Biohaven Ltd. (NYSE:BHVN) is one of the best low priced biotech stocks to invest in. On April 13, Canaccord initiated coverage of Biohaven Ltd. (NYSE:BHVN) with a Buy rating and set a $21 price target on the stock. The firm told investors in a research note that the company is in the process of developing novel therapeutics for obesity, immunology, neuroscience, and oncology indications. Canaccord views the stock as undervalued based on the company’s opakalim opportunity alone, and recommends buying the shares into the focal epilepsy readout, which the firm sees as presenting “significant upside potential.”
Biohaven Ltd. (NYSE:BHVN) also received a rating update from Citi on April 2, with the firm lifting the price target on the stock to $17 from $14 while maintaining a Buy rating on the shares. The firm told investors that it sees an attractive risk/reward at current share levels into the company’s 2026 catalysts. It also said that it sees the recent competitor data in focal epilepsy to be very positive for the company’s Phase 3 opakalim trial, which has a readout in the second half of 2026.
Biohaven Ltd. (NYSE:BHVN) is a global clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of therapies for people living with neurological and neuropsychiatric diseases.
While we acknowledge the potential of BHVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
